Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Fulcrum Therapeutics, Inc.
< Previous
1
2
Next >
Fulcrum Therapeutics to Participate in Upcoming December Conferences
November 26, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
November 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
November 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
November 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate in Upcoming September Conferences
August 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
August 19, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 31, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 24, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
SNY
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
SNY
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 28, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FULC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.